Cormorant, Hillhouse, venBio co-lead $47.1m round for Apellis

Cormorant Asset Management, Hillhouse Capital Group and venBio Global Strategic Fund came in as new investors in a $47.1m Series D round for Apellis Pharmaceuticals.